FDA Slaps Concordia Pharmaceuticals Over ADHD Drug Promo
Concordia Pharmaceuticals Inc. marketed attention deficit hyperactivity disorder drug Kapvay to doctors with a sales pitch that misstated dosing, mischaracterized the product's role in treatment and largely failed to discuss risks,...To view the full article, register now.
Already a subscriber? Click here to view full article